OncoMatch/Clinical Trials/NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Is NCT06106945 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AZD0305 for multiple myeloma.
Treatment: AZD0305 — This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor (bortezomib)
Participants must have received at least 3 prior lines of treatment which include a proteasome inhibitor (e.g., bortezomib)
Must have received: immunomodulator (lenalidomide)
Participants must have received at least 3 prior lines of treatment which include...an immunomodulator (e.g., lenalidomide)
Must have received: anti-CD38 antibody (daratumumab)
Participants must have received at least 3 prior lines of treatment which include...an anti-CD38 antibody (e.g., daratumumab)
Cannot have received: anti-GPRC5D therapy
Participants who have previously received anti-GPRC5D...treatment.
Cannot have received: MMAE-containing treatment
Participants who have previously received...MMAE-containing treatment.
Cannot have received: allogenic stem cell transplant
Participants who have previously received allogenic stem cell transplant
Cannot have received: autologous stem cell transplant
Exception: within 3 months before the first dose of study intervention
participant has received autologous stem cell transplant within 3 months before the first dose of study intervention
Lab requirements
Blood counts
Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.
Kidney function
Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.
Liver function
Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.
Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Irvine, California
- Research Site · Atlanta, Georgia
- Research Site · Boston, Massachusetts
- Research Site · Ann Arbor, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify